Sherry Korczynski

CIK: 0002026090

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (18.2%)

Position reduction

Option Exercises (M)1 (9.1%)

Derivative conversions

Awards (A)4 (36.4%)

Compensation grants

Other (G, F, J, C, D, …)4 (36.4%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AQST

Aquestive Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

AQST
Aquestive Therapeutics, Inc.
Sep 9, 2026
Exercise(M)
Direct
8.8K shares at avg. $2.65$23K
AQST
Aquestive Therapeutics, Inc.
Sep 9, 2026
Sale(S)
Direct
8.8K shares at avg. $5.22$46K
AQST
Aquestive Therapeutics, Inc.
Aug 14, 2026
Tax Payment(F)
Direct
2.7K shares at avg. $4.25$12K
AQST
Aquestive Therapeutics, Inc.
Jun 8, 2026
Tax Payment(F)
Direct
2.7K shares-
AQST
Aquestive Therapeutics, Inc.
Mar 10, 2026
Sale(S)
Direct
15.7K shares at avg. $4.17$66K
AQST
Aquestive Therapeutics, Inc.
Mar 9, 2026
Award(A)
Direct
75K shares-
AQST
Aquestive Therapeutics, Inc.
Aug 14, 2025
Award(A)
Direct
25K shares-
AQST
Aquestive Therapeutics, Inc.
Jun 9, 2025
Tax Payment(F)
Direct
2.7K shares at avg. $3.54$10K
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Award(A)
Performance Stock Units
Direct
67.5K shares-
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Award(A)
Direct
90K shares-
AQST
Aquestive Therapeutics, Inc.
Mar 7, 2025
Tax Payment(F)
Direct
5.4K shares at avg. $2.65$14K

		Type	Shares	Price		Ownership
Sep 9, 2026	AQST Aquestive Therapeutics, Inc.	Exercise(M)	8,750	$2.65	$23,188	Direct
Sep 9, 2026	AQST Aquestive Therapeutics, Inc.	Sale(S)	8,750	$5.22	$45,675	Direct
Aug 14, 2026	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	2,714	$4.25	$11,535	Direct
Jun 8, 2026	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	2,714	-	$0	Direct
Mar 10, 2026	AQST Aquestive Therapeutics, Inc.	Sale(S)	15,741	$4.17	$65,687	Direct
Mar 9, 2026	AQST Aquestive Therapeutics, Inc.	Award(A)	75,000	-	$0	Direct
Aug 14, 2025	AQST Aquestive Therapeutics, Inc.	Award(A)	25,000	-	-	Direct
Jun 9, 2025	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	2,714	$3.54	$9,608	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Award(A) Performance Stock Units	67,500	-	-	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Award(A)	90,000	-	-	Direct
Mar 7, 2025	AQST Aquestive Therapeutics, Inc.	Tax Payment(F)	5,428	$2.65	$14,384	Direct

1-11 of 11 transactions

About Korczynski Sherry

Korczynski Sherry (SEC CIK 0002026090) files insider reports with the SEC as Chief Commercial Officer of Aquestive Therapeutics, Inc. (AQST).

Signal8 holds 8 ownership filings by Korczynski Sherry, all Form 4s, filed between Mar 11, 2025 and Sep 11, 2026. Those filings report 11 transactions, from Mar 7, 2025 to Sep 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Korczynski Sherry's filings is in WARREN, NJ.

Recent filings by Korczynski Sherry

Sep 9, 2026: Option exercise of AQST shares (Form 4, code M).
Sep 9, 2026: Open-market sale of AQST shares (Form 4, code S).
Aug 14, 2026: Tax withholding of AQST shares (Form 4, code F).
Jun 8, 2026: Tax withholding of AQST shares (Form 4, code F).
Mar 10, 2026: Open-market sale of AQST shares (Form 4, code S).

Other insiders filing for Aquestive Therapeutics, Inc. (AQST)

Cochran John, Director
Barber Daniel, President and CEO
Daly Richard J, Director
Boyd Peter E., Chief People Officer
Jung Cassie, Chief Operating Officer
Krop Julie, Director

How to read Form 4 transaction codes